Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer

Ani Balmanoukian

Ani Balmanoukian

Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study

Scott Antonia, Sarah B Goldberg, Ani Balmanoukian, Jamie E Chaft, Rachel E Sanborn, Ashok Gupta, Rajesh Narwal, Keith Steele, Yu Gu, Joyson J Karakunnel, Naiyer A Rizvi

Lancet Oncol 2016; 17: 299–308
Published Online; February 5, 2016
http://dx.doi.org/10.1016/
S1470-2045(15)00544-6

More publications from Ani Balmanoukian

2021-11-06T07:28:09+01:00November 6, 2021|Other article for therapists|

Share This Story, Choose Your Platform!

Go to Top